Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REATA PHARMACEUTICALS INCRETA · Entity 12293 | Chief Development Officer | February 25, 2019 | February 27, 2019 |
| Skye Bioscience, Inc.SKYE · Entity 8098 | Director | February 29, 2024 | March 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REATA PHARMACEUTICALS INC
Report date February 25, 2019 · Filed February 27, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | Direct | 8,620 |
Ending reported balance
After 2019-02-26 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2019-02-25 · Conversion · Acquired 15,183 · Balance 23,803 F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F2: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Row 2 · 2019-02-25 · Sale · Disposed 15,183 · Balance 8,620 F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. Row 3 · 2019-02-26 · Conversion · Acquired 25,184 · Balance 33,804 F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F2: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Row 4 · 2019-02-26 · Sale · Disposed 16,817 · Balance 16,987 F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. Row 5 · 2019-02-26 · Sale · Disposed 8,367 · Balance 8,620 F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.00 · Expires 2026-05-25 | Direct | 92,967 |
Reported balance
After 2019-02-25 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-02-25 · Exercise / conversion · Disposed 15,183 · Balance 92,967 F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F3: The options, representing a right to purchase a total of 108,150 shares, vest in sixteen equal quarterly installments beginning on August 25, 2016. F2: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.00 · Expires 2026-05-25 | Direct | 76,150 |
Reported balance
After 2019-02-26 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-02-26 · Exercise / conversion · Disposed 16,817 · Balance 76,150 F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F3: The options, representing a right to purchase a total of 108,150 shares, vest in sixteen equal quarterly installments beginning on August 25, 2016. F2: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.62 · Expires 2023-06-15 | Direct | 0 |
Reported balance
After 2019-02-26 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-02-26 · Exercise / conversion · Disposed 8,367 · Balance 0 F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F4: The options, representing a right to purchase a total of 82,287 shares, vested in twenty equal quarterly installments beginning on September 15, 2013. F2: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. |
| Class B common stockSEC Table II · derivative / convertible security | Direct | 15,183 |
Reported balance
After 2019-02-25 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-02-25 · Exercise / conversion · Acquired 15,183 · Balance 15,183 F2: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. |
| Class B common stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-02-25 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-02-25 · Conversion · Disposed 15,183 · Balance 0 F2: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. |
| Class B common stockSEC Table II · derivative / convertible security | Direct | 16,817 |
Reported balance
After 2019-02-26 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-02-26 · Exercise / conversion · Acquired 16,817 · Balance 16,817 F2: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. |
| Class B common stockSEC Table II · derivative / convertible security | Direct | 25,184 |
Reported balance
After 2019-02-26 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-02-26 · Exercise / conversion · Acquired 8,367 · Balance 25,184 F2: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. |
| Class B common stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-02-26 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2019-02-26 · Conversion · Disposed 25,184 · Balance 0 F2: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018.
F2: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.
F3: The options, representing a right to purchase a total of 108,150 shares, vest in sixteen equal quarterly installments beginning on August 25, 2016.
F4: The options, representing a right to purchase a total of 82,287 shares, vested in twenty equal quarterly installments beginning on September 15, 2013.
Skye Bioscience, Inc.
Report date February 29, 2024 · Filed March 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.56 · Expires 2034-03-01 | Direct | 35,000 |
Reported balance
After 2024-02-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-29 · Grant · Acquired 35,000 · Balance 35,000 F1: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 23, 2018 Filed Oct 24, 2018 11:01 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass A common stock | 14,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-056013 · doc4.xml · nonDerivative · entry 1 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F2 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 11:16 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass B common stock · Derivative | 4,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-041949 · doc4.xml · derivative · entry 5 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 4,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F2 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 11:16 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionClass B common stock · Derivative | 4,750 | $11.62 | $55,195.00 |
DisclosureSEC source: 0001209191-18-041949 · doc4.xml · derivative · entry 4 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,750 Underlying: Class A common stock · 4,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F2 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 11:16 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,750 | $0.00 Strike: $11.62 | $0.00 |
DisclosureSEC source: 0001209191-18-041949 · doc4.xml · derivative · entry 3 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,037 Underlying: Class B common stock · 4,750 shares Expires 2023-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F3 · derivative.exercise_date: The options, representing a right to purchase a total of 82,287 shares, vested in twenty equal quarterly installments beginning on September 15, 2013. F2 · derivative.underlying: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 11:16 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 4,750 | $36.62 | $173,945.00 |
DisclosureSEC source: 0001209191-18-041949 · doc4.xml · nonDerivative · entry 2 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 11:16 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass A common stock | 4,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-041949 · doc4.xml · nonDerivative · entry 1 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F2 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 11:37 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass B common stock · Derivative | 28,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-036228 · doc4.xml · derivative · entry 5 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 28,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F2 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 11:37 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionClass B common stock · Derivative | 28,500 | $11.62 | $331,170.00 |
DisclosureSEC source: 0001209191-18-036228 · doc4.xml · derivative · entry 4 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,500 Underlying: Class A common stock · 28,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F2 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 11:37 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 28,500 | $0.00 Strike: $11.62 | $0.00 |
DisclosureSEC source: 0001209191-18-036228 · doc4.xml · derivative · entry 3 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,787 Underlying: Class B common stock · 28,500 shares Expires 2023-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F3 · derivative.exercise_date: The option, representing a right to purchase a total of 82,287 shares, vests in twenty equal quarterly installments beginning September 15, 2013, subject to continued service through each vesting date. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 11:37 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 28,500 | $36.62 | $1,043,670.00 |
DisclosureSEC source: 0001209191-18-036228 · doc4.xml · nonDerivative · entry 2 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 11:37 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass A common stock | 28,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-036228 · doc4.xml · nonDerivative · entry 1 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F2 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| December 06, 2017 Filed Dec 7, 2017 16:10 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | GrantEmployee Stock Option (right to buy) · Derivative | 84,800 | $0.00 Strike: $24.75 | $0.00 |
DisclosureSEC source: 0001209191-17-064410 · doc4.xml · derivative · entry 1 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,800 Underlying: Class B common stock · 84,800 shares Expires 2027-12-06 F1 · derivative.exercise_date: The options vest in sixteen equal quarterly installments beginning on March 6, 2018, subject to continued service through each vesting date. F2 · derivative.underlying: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 16:04 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | GrantEmployee Stock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $22.57 | $0.00 |
DisclosureSEC source: 0001209191-16-154136 · doc4.xml · derivative · entry 1 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Class B common stock · 85,000 shares Expires 2026-12-07 F1 · derivative.exercise_date: The options vest in twenty equal quarterly installments beginning on March 7, 2017, subject to continued service through each vesting date. F2 · derivative.underlying: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.